Hansa Biopharma Q3 update: Slow progress ahead of 2024 - Redeye

Redeye updates its outlook on Hansa Biopharma, anticipating gradual launch support during 2023 and supporting pipeline progress over the next 12 months. We make a negative revision reflecting the slow launch progress and a more stretched funding outlook. Our Base Case is SEK100 (175) with a Bull Case of SEK200 (400) and a Bear Case of SEK15 (45).

Länk till analysen i sin helhet: https://www.redeye.se/research/951718/hansa-biopharma-q3-update-slow-progress-ahead-of-2024?utm_source=finwire&utm_medium=RSS